We rank companies based on fund manager, research analyst and news sentiment
AMPE

Ampio Pharmaceuticals Inc.
AMPE

 

About: Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee ("OAK") as part of its OA-201 development program ("OA-201 program" or "OA-201").

Employees: 6

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

1,048% more capital invested

Capital invested by funds: $8.43K [Q3] → $96.7K (+$88.3K) [Q4]

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

8% more funds holding

Funds holding: 25 [Q3] → 27 (+2) [Q4]

5.42% more ownership

Funds ownership: 0.31% [Q3] → 5.73% (+5.42%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for AMPE.

Financial journalist opinion